Press release -
Booming interest in probiotic solutions for women’s health
A probiotic capsule that can help reduce the risk of vaginal infections is now available in Colombia – as the 37th country in the world.
Statistically every woman will experience occasional disorders of the vaginal flora, which may lead to more serious conditions possibly lowering the comfort and quality of the woman’s life. However, a specific probiotic capsule taken orally can restore and maintain a healthy vaginal flora which can help reduce the risk of infections.
New distribution agreement in Colombia
The concept has gained popularity all over the world in recent years and now Chr. Hansen has signed an agreement with one of the major pharmaceutical companies in Colombia: Laboratórios Synthesis will be Chr. Hansen’s sole distributor of its female health product - a dietary supplement which has been approved by the Colombian medical authorities INVIMA. In Colombia the product will be sold under the brand name “BioBactro”.
“Women all over the world rely on the effect and user-friendliness of this concept and we are pleased to see it launched in Colombia as country no. 37,” says Christian Due Jensen, Regional Sales Manager, Human Health & Nutrition, Chr. Hansen. “The oral dosage form is perceived as easy and convenient by consumers, and I am not surprised to see this extensively documented concept being launched in more and more markets.”
Expansion into neighbouring countries
“Our agreement with Laboratórios Synthesis is one of several new probiotic deals for Chr. Hansen in Latin America. Moving ahead we are stepping up our activities in this bustling emerging market with the aim to become a key player in probiotics by actively offering our internationally recognized solutions to dietary supplements producers and pharmaceutical companies across the region,” Christian Due Jensen concludes.
Luis Palacios, Managing Director, Laboratórios Synthesis comments: “Being the global market leader within probiotics Chr. Hansen is the perfect partner for us. Reliability is a key value for our company and with Chr. Hansen we can rely on the best clinically documented probiotic strains for women’s health. Starting in Colombia we look forward to also rolling out BioBactro in pharmacies in Venezuela, Peru, Equador and Bolivia.”
The company has just presented the new product at a women’s health conference attended by 200 medical doctors in Cartagena, Colombia.
Topics
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.
